# Kaiku Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kaiku-health

- Industry: Healthcare IT
- Headquarters: Helsinki, Finland
- Website: www.kaikuhealth.com
- Total disclosed funding: $6.6M
- Latest round: Series A (Apr 5, 2018)
- Investors on record: 6

## About

Kaiku Health Ltd. specializes in digital health solutions for cancer care, offering a platform that enhances patient monitoring and support, ultimately improving clinical outcomes through personalized interventions and real-world data collection.Founded in 2012, Kaiku Health Ltd. operates from its headquarters in Helsinki, Finland. The company is committed to advancing cancer treatment through its innovative digital health intervention platform. In May 2020, Elekta AB acquired Kaiku Health Ltd. Financial terms of the acquisition were not disclosed. Kaiku Health has secured a total funding amount of EUR 4.40 mn in its Series A funding round, with investors including Athensmed Oy, Debiopharm Innovation Fund, Finnish Industry Investment, Metsola Ventures, Prodeko Ventures, and Reaktor Ventures. The company has completed four funding deals, the most recent being on May 19, 2020.Kaiku Health's advanced digital health intervention platform enables personalized cancer care by providing digital patient monitoring and support. This platform is utilized by healthcare institutions and cancer centers globally, particularly in Europe and North America. Its key features include customizable modules that allow healthcare providers to monitor patient-reported outcomes effectively. By employing machine learning to analyze this data, Kaiku Health enhances early symptom detection, thereby improving patient safety and overall satisfaction.In the most recent year of 2023, Kaiku Health reported a revenue of EUR 2,511,580.90, with an EBITDA of EUR -1,503,293.10. The company primarily generates revenue through subscriptions and partnerships with healthcare providers, allowing for ongoing access to its platform and features designed for enhancing treatment coordination.Kaiku Health aims to expand its product offerings by developing new therapy-specific modules designed for various cancer treatments, with anticipated launches in the coming year. Additionally, the company is targeting growth in new geographic markets, particularly in North America and Asia, over the next two years. The recent funding from the Series A round will support these initiatives, providing resources for product development and market entry strategies.

## Funding rounds

- Series A, Apr 5, 2018, $5.4M — Finnish Industry Investment, Reaktor Ventures, Metsola Ventures, Prodeko Ventures, Debiopharm Innovation Fund, Athensmed Oy
- Seed, Apr 22, 2016, $0.9M — Reaktor Ventures, Metsola Ventures
- Seed, Sep 1, 2013, $0.2M — Reaktor Ventures

## Investors

- Reaktor Ventures — Seed, Series A
- Metsola Ventures — Seed, Series A
- Finnish Industry Investment — Series A
- Prodeko Ventures (https://capitalatlas.ai/funds/prodeko-ventures) — Series A
- Debiopharm Innovation Fund (https://capitalatlas.ai/funds/debiopharm-innovation-fund) — Series A
- Athensmed Oy — Series A